ENDRA Life Sciences (NDRA) EBITDA (2016 - 2026)

ENDRA Life Sciences has disclosed EBITDA across 11 years of filings, most recently posting -$2.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 47.95% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$2.2 million (up 77.06% YoY), while the FY2025 annual figure was -$1.5 million, up 86.36% from the prior year.
• EBITDA eased to -$2.2 million in Q1 2026, from $2.7 million in the prior quarter.
• Over the last five years, EBITDA for NDRA reached as high as $2.7 million in Q4 2025 and fell as low as -$4.3 million in Q4 2024.
• The 5-year median for EBITDA is -$2.8 million (2024), against an average of -$2.2 million.
• Annual changes were most pronounced in 2024 — EBITDA sank 194.75% — and 2025, when it surged 162.03%.
• A 5-year view of EBITDA shows it stood at -$3.3 million in 2022, then surged by 56.0% to -$1.5 million in 2023, then slumped by 194.75% to -$4.3 million in 2024, then surged by 162.03% to $2.7 million in 2025, then tumbled by 181.56% to -$2.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.2 million, $2.7 million, and -$1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.